194 related articles for article (PubMed ID: 22106112)
1. Practice Gaps. Optimizing antimalarial therapy for cutaneous lupus erythematosus: comment on "Response to antimalarial agents in cutaneous lupus erythematosus".
Callen JP
Arch Dermatol; 2011 Nov; 147(11):1267-8. PubMed ID: 22106112
[No Abstract] [Full Text] [Related]
2. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
[TBL] [Abstract][Full Text] [Related]
3. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
4. Increased Myeloid Dendritic Cells and TNF-α Expression Predicts Poor Response to Hydroxychloroquine in Cutaneous Lupus Erythematosus.
Zeidi M; Kim HJ; Werth VP
J Invest Dermatol; 2019 Feb; 139(2):324-332. PubMed ID: 30227141
[TBL] [Abstract][Full Text] [Related]
5. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Feldmann R; Salomon D; Saurat JH
Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
[TBL] [Abstract][Full Text] [Related]
6. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
Ezra N; Jorizzo J
Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
[TBL] [Abstract][Full Text] [Related]
7. [Quinacrine in the treatment of cutaneous lupus erythematosus: practical aspects and a case series].
González-Sixto B; García-Doval I; Oliveira R; Posada C; García-Cruz MA; Cruces M
Actas Dermosifiliogr; 2010; 101(1):54-8. PubMed ID: 20109393
[TBL] [Abstract][Full Text] [Related]
8. Management of antimalarial-refractory cutaneous lupus erythematosus.
Callen JP
Lupus; 1997; 6(2):203-8. PubMed ID: 9061669
[No Abstract] [Full Text] [Related]
9. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine.
Cavazzana I; Sala R; Bazzani C; Ceribelli A; Zane C; Cattaneo R; Tincani A; Calzavara-Pinton PG; Franceschini F
Lupus; 2009 Jul; 18(8):735-9. PubMed ID: 19502270
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
Kwatra SG
J Am Acad Dermatol; 2015 Aug; 73(2):e79. PubMed ID: 26184008
[No Abstract] [Full Text] [Related]
11. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
[TBL] [Abstract][Full Text] [Related]
12. Impact of smoking in cutaneous lupus erythematosus.
Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
[TBL] [Abstract][Full Text] [Related]
13. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
Teboul A; Arnaud L; Chasset F
J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
[TBL] [Abstract][Full Text] [Related]
14. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
15. Rhabdomyolysis associated with quinacrine therapy in a patient with chronic cutaneous lupus erythematosus.
Creel N; Werth V
J Drugs Dermatol; 2005; 4(2):225-7. PubMed ID: 15776783
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of hydroxychloroquine on cutaneous lupus erythematosus in a Japanese girl.
Yamamoto T; Hiraiwa T
J Dermatol; 2014 Apr; 41(4):357-9. PubMed ID: 24617496
[No Abstract] [Full Text] [Related]
17. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
Wozniacka A; McCauliffe DP
Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
[TBL] [Abstract][Full Text] [Related]
18. Increased CD69+CCR7+ circulating activated T cells and STAT3 expression in cutaneous lupus erythematosus patients recalcitrant to antimalarials.
Zeidi M; Chen KL; Patel J; Desai K; Kim HJ; Chakka S; Lim R; Werth VP
Lupus; 2022 Apr; 31(4):472-481. PubMed ID: 35258358
[TBL] [Abstract][Full Text] [Related]
19. The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
Mittal L; Werth VP
J Am Acad Dermatol; 2017 Aug; 77(2):374-377. PubMed ID: 28711090
[No Abstract] [Full Text] [Related]
20. Candidate drug replacements for quinacrine in cutaneous lupus erythematosus.
Yan D; Borucki R; Sontheimer RD; Werth VP
Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33082164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
